Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR3 S131L |
| Therapy | Infigratinib |
| Indication/Tumor Type | head and neck squamous cell carcinoma |
| Response Type | decreased response |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 S131L | head and neck squamous cell carcinoma | decreased response | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, a head and neck squamous cell carcinoma cell line expressing FGFR3 S131L demonstrated decreased sensitivity to Truseltiq (infigratinib) compared to cells expressing wild-type FGFR3 in culture (PMID: 27053219). | 27053219 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27053219) | Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. | Full reference... |